Loading…
Precision-oncology biotech developing targeted small molecules for prostate cancer and EGFR/HER2-mutant lung cancer.
Precision-oncology biotech developing targeted small molecules for prostate cancer and EGFR/HER2-mutant lung cancer.
Has no approved product, so it earns nothing from sales and pays for trials by selling shares and from cash raised before. Its two lead drugs target prostate cancer and lung cancer with specific gene changes; partnering with a larger drugmaker is the usual route to commercialise later.
Moat: none (IP / patents). Pre-commercial; competes with larger, better-funded oncology programs at bigger companies.
Headquarters: South San Francisco, California, US · Founded: 2017 · Employees: 104
Size Oric Pharmaceuticals (ORIC) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $914M, the 2306th largest of 3,117 United States companies the cockpit tracks. Shares closed at $8.82 on 6 Nov 2026.
Performance Over six months the shares fell 0.3%, against -14.9% for the median peer and -1.1% for the United States market (cap-weighted) — 5th highest of 20 in its peer set.
Capital Return on invested capital runs 113.9 points below its cost of capital (11.0% WACC).
Short interest Short interest is 14.9% of the free float (15 Oct 2026).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$1.14M | -$1.22M | -$1.11M | -$1.03M | -$966,000 |
| EBITDA | -$155M | -$142M | -$142M | -$110M | -$85.8M |
| Net income | -$140M | -$129M | -$128M | -$101M | -$89.1M |
| Free cash flow | -$115M | -$114M | -$114M | -$86.8M | -$77.6M |
| Capital expenditure | $620,000 | $712,000 | $1.19M | $849,000 | $2.08M |
| Total debt | $3.33M | $7.44M | $9.36M | $10.2M | $12.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Oric Pharmaceuticals ORIC | $914M | 0% | n/a | n/a | n/a | n/a |
| Johnson & Johnson JNJ | $665B | +26% | +8% | 26% | 7.0× | 3.5% |
| Pfizer PFE | $168B | +14% | +1% | 26% | 3.4× | -4.3% |
| AstraZeneca AZN.L | $291B | +1% | +5% | 23% | 5.1× | 14.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ORIC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -26.7% | -6.6% | lowest of 20 |
| 6-month return | -0.3% | -14.9% | 5th highest of 20 |
| Distance from 52-week high | -39.9% | -33.9% | 7th lowest of 21 |
| ROIC minus cost of capital | -113.9 pp | -2.2 pp | lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Oric Pharmaceuticals ORIC | United States | $914M | 0% | n/a | n/a | n/a | n/a | n/a |
| Bide Pharmatech 688073.SS | China | $912M | +5% | +10% | 19% | 3.6× | 16.7% | +27.7% |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $909M | -33% | -14% | -29% | 5.2× | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $909M | -65% | -11% | -3% | 5.9× | -1.2% | -39.5% |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $907M | -12% | -25% | 2% | 2.9× | 16.2% | -0.2% |
| Dezhan Healthcare 000813.SZ | China | $928M | -18% | -10% | -121% | 15.8× | n/a | n/a |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $930M | -24% | -6% | 5% | 4.4× | 33.2% | +4.2% |
| Nxera Pharma 4565.T | Japan | $932M | +63% | +24% | 14% | 5.1× | 16.2% | +27.3% |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $894M | -8% | -1% | -2% | 6.1× | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $893M | -27% | +1% | 0% | 7.1× | n/a | n/a |
| Aarti Pharmalabs AARTIPHARM.NS | India | $892M | +19% | +13% | 18% | 4.3× | n/a | n/a |
| Hunan Warrant Pharmaceutical 688799.SS | China | $942M | -20% | +5% | 9% | 4.7× | n/a | n/a |
| Corvus Pharmaceuticals CRVS | United States | $887M | -32% | n/a | n/a | n/a | n/a | n/a |
| City Therapeutics CTY | United States | $944M | n/a | +388% | -442% | n/a | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $948M | -10% | -6% | 3% | 1.0× | -6.8% | -0.7% |
| Aktis Oncology AKTS | United States | $880M | -15% | +337% | -1,150% | 57.5× | n/a | n/a |
| Immatics IMTX | United States | $952M | -44% | -65% | -556% | 10.7× | n/a | n/a |
| Daewoong Pharm 069620.KS | South Korea | $874M | -30% | +9% | 12% | 0.7× | n/a | n/a |
| Pharming PHARM.AS | Netherlands | $874M | -2% | +2% | 9% | 2.1× | 2.5% | +12.4% |
| Hygeia Healthcare 6078.HK | Hong Kong | $861M | -7% | +2% | 14% | 1.9× | 4.8% | +22.5% |
| Procter & Gamble Health PGHL.NS | India | $971M | +4% | +13% | 31% | 6.3× | 5.5% | +9.3% |